文献速递消化道肿瘤与早癌肝病消化内镜

EB病毒相关肝内胆管癌的临床病理、肿瘤免疫微环境及基因组特征

Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
PubMed 文献 · J Hepatol · 2020-11-17

该研究在中国南方303例肝内胆管癌(ICC)中采用原位杂交检测EBV,发现EBVaICC占6.6%,与EBV潜伏I型感染及克隆性EBV分离株相关。EBVaICC多见于女性、年轻、孤立肿瘤、高HBV感染率且肝硬化少见,淋巴上皮瘤样(LEL)亚型更常见,肿瘤免疫微环境(TIME)成分显著更大。LEL亚型EBVaICC的CD20+ B细胞和CD8+ T细胞密度及比例显著增加,2年生存率显著更高;TILs中PD-1和PD-L1及肿瘤细胞PD-L1过表达,肿瘤细胞高PD-L1表达和高CD8+ TIL密度在EBVaICC中更常见。7个基因在至少3例患者中突变,EBVaICC突变模式与肝吸虫相关胆管癌及HBV相关ICC不同。

要点

  • EBVaICC占ICC的6.6%,与EBV潜伏I型感染及克隆性EBV分离株相关。
  • EBVaICC的TIME成分显著更大,LEL亚型CD20+ B细胞和CD8+ T细胞密度及比例显著增加,2年生存率显著更高。
  • EBVaICC中TILs的PD-1和PD-L1及肿瘤细胞PD-L1过表达,肿瘤细胞高PD-L1表达和高CD8+ TIL密度更常见。

核心结论

  • EBVaICC作为ICC的一个亚群,具有独特的病因学、临床病理和遗传学特征,TIME成分显著更大。
  • EBVaICC患者可能是免疫检查点治疗的候选者。

研究设计与样本

  • 研究评估了303例肝内胆管癌(ICC),采用原位杂交检测EBV。
  • 比较EBVaICC与非EBVaICC的临床病理参数,并通过免疫组化、双重染色、巢式PCR、多重免疫荧光染色、荧光原位杂交和全外显子测序分析EBVaICC的EBV感染状态、肿瘤浸润淋巴细胞(TILs)和基因组特征。

主要发现

  • EBVaICC占ICC的6.6%,与EBV潜伏I型感染和克隆性EBV分离株相关。
  • EBVaICC患者更常为女性、年轻、孤立肿瘤、HBV感染率更高、肝硬化较少见;LEL亚型在EBVaICC中更常见。
  • EBVaICC的TIME成分显著大于非EBVaICC;LEL亚型EBVaICC的CD20+ B细胞和CD8+ T细胞密度及比例显著增加,2年生存率显著高于传统EBVaICC和非EBVaICC。
  • TILs中PD-1和PD-L1及肿瘤细胞PD-L1在EBVaICC中过表达;肿瘤细胞高PD-L1表达和高CD8+ TIL密度在EBVaICC中显著更常见。
  • 7个基因(MUC4、DNAH1、GLI2、LIPE、MYH7、RP11-766F14.2和WDR36)在至少3例患者中突变;EBVaICC突变模式与肝吸虫相关胆管癌及HBV相关ICC不同。

临床怎么用

  • 对ICC患者可考虑检测EBV状态以识别EBVaICC亚型。
  • EBVaICC患者,尤其是LEL亚型,可能从免疫检查点抑制剂治疗中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Little is known about Epstein-Barr virus (EBV)-associated intrahepatic cholangiocarcinoma (EBVaICC) because of its rarity. We aimed to comprehensively investigate the clinicopathology, tumor immune microenvironment (TIME) and genomic landscape of this entity in southern China. METHODS: We evaluated 303 intrahepatic cholangiocarcinomas (ICCs) using in situ hybridization for EBV. We compared clinicopathological parameters between EBVaICC and nonEBVaICC, and we analyzed EBV infection status, tumor-infiltrating lymphocytes (TILs) and genomic features of EBVaICC by immunohistochemistry, double staining, nested PCR, multiplex immunofluorescence staining, fluorescence in situ hybridization and whole-exome sequencing. RESULTS: EBVaICC accounted for 6.6% of ICCs and was associated with EBV latency type I infection and clonal EBV isolates. Patients with EBVaICC were more often female and younger, with solitary tumors, higher HBV infection rates and less frequent cirrhosis; the lymphoepithelioma-like (LEL) subtype was more common in EBVaICC. EBVaICC was associated with a significantly larger TIME component than nonEBVaICC. The LEL subtype of EBVaICC - associated with a significantly increased density and proportion of CD20+ B cells and CD8+ T cells - was associated with significantly higher 2-year survival rates than conventional EBVaICC and nonEBVaICC. Both PD-1 and PD-L1 in TILs, and PD-L1 in tumor cells, were overexpressed in EBVaICC. High PD-L1 expression in tumor cells and high CD8+ TIL densities were significantly more common in EBVaICC than in nonEBVaICC. Seven genes (MUC4, DNAH1, GLI2, LIPE, MYH7, RP11-766F14.2 and WDR36) were mutated in at least 3 patients. EBVaICC had a different mutational pattern to liver fluke-associated cholangiocarcinoma and HBV-associated ICC. CONCLUSIONS: EBVaICC, as a subset of ICC, has unique etiological, clinicopathological and genetic characteristics, with a significantly larger TIME component. Paradoxically, patients with EBVaICC could be candidates for immune checkpoint therapy. LAY SUMMARY: Epstein-Barr virus (EBV) is associated with a subtype of intrahepatic cholangiocarcinoma, with unique clinicopathological and genetic characteristics. The tumor immune microenvironment is also different in this tumor subtype and patients with EBV-associated intrahepatic cholangiocarcinoma may respond well to immune checkpoint inhibitors.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Huang YH, Zhang CZ, Huang QS, et al. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. J Hepatol. 2020. PMID: 33212090. doi:10.1016/j.jhep.2020.10.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。